N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Chromaffin-tissue Derived Tumors
Both
Chromaffin-tissue Derived Tumors
Trial Information
Inclusion Criteria:
- Age + 18 years. The women in ages to procreate have to have an effective
contraception or a negative pregnancy test (in the absence of effective
contraception) Having a radiological and functional imaging (balance
sheet(assessment) pré--IBZM) considered adapted and complete for the pathology.
- Having a phéochromocytome or a paragangliome proving a surgical operation in view of
the data of the balance sheet(assessment) pré--IBZM.
- With or without allergy in the iodine.
Exclusion Criteria:
- NEM2A or 2B.
- Malignant Forms which do not recover from an even partial, surgical
gesture(movement).
- Pregnant Women or in the course of feeding.
- Women in age to procreate without effective contraception, with positive pregnancy
test.
- Renal insufficiency
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
The aim of the present study is to evaluate the feasibility of 123I-IBZM (a D2 agonist radiolabelled with 123I) in patients with PHEO and/or PGL. Diagnostic accuracy will be also compared to traditional SPECT imaging procedures.
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
DAVID TAIEB
Investigator Role:
Principal Investigator
Investigator Affiliation:
Assistance Publique Hopitaux De Marseille
Authority:
France: Ministry of Health
Study ID:
2008/09
NCT ID:
NCT00875407
Start Date:
February 2009
Completion Date:
Related Keywords:
- Chromaffin-tissue Derived Tumors
Name | Location |
|---|
